Published in Int J Cardiol on April 25, 2007
Relation between Body Humors and Hypercholesterolemia: An Iranian Traditional Medicine Perspective Based on the Teaching of Avicenna. Iran Red Crescent Med J (2012) 4.30
Acute coronary syndrome in young adults from oman: results from the gulf registry of acute coronary events. Heart Views (2010) 0.88
Demographics and Angiographic Findings in Patients under 35 Years of Age with Acute ST Elevation Myocardial Infarction. J Tehran Heart Cent (2011) 0.87
Subclinical coronary atherosclerosis in young adults: prevalence, characteristics, predictors with coronary computed tomography angiography. Int J Cardiovasc Imaging (2012) 0.81
Acute coronary syndrome in the young: clinical characteristics, risk factors and prognosis. Open Cardiovasc Med J (2014) 0.78
Risk factors for long-term outcome of drug-eluting stenting in adults with early-onset coronary artery disease. Int J Med Sci (2014) 0.77
Acute myocardial infarction: Clinical features and outcomes in young adults in Singapore. World J Cardiol (2012) 0.77
Non-culprit coronary lesions in young patients have higher rates of atherosclerotic progression. Int J Cardiovasc Imaging (2015) 0.76
Prevalence and risk factors of premature coronary artery disease in patients undergoing coronary angiography in Kurdistan, Iraq. BMC Cardiovasc Disord (2015) 0.75
Clinical Profile and Long-Term Prognostic Factors of a Young Chinese Han Population (≤ 40 Years) Having ST-Segment Elevation Myocardial Infarction. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2015) 0.75
Two-year prognosis after acute coronary syndrome in younger patients: Association with feeling depressed in the prior year, and BDI-II score and Endothelin-1. J Psychosom Res (2017) 0.75
Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (2007) 2.95
[The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers]. Rev Esp Cardiol (2006) 2.63
Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol (2005) 2.47
Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol (2012) 2.32
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv (2012) 2.07
New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation. Rev Esp Cardiol (Engl Ed) (2011) 2.01
Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol (2008) 1.89
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood (2012) 1.74
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun (2012) 1.67
Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood (2012) 1.65
AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. Haematologica (2008) 1.62
Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol (2008) 1.57
Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost (2015) 1.49
Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Rev Esp Cardiol (Engl Ed) (2011) 1.46
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery. Ann Thorac Surg (2006) 1.45
[Annexin V levels in survivors of early myocardial infarction]. Rev Esp Cardiol (2002) 1.44
Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting. Thromb Haemost (2011) 1.43
[Minimum salvaged myocardium after rescue percutaneous coronary intervention: quantification by cardiac magnetic resonance]. Rev Esp Cardiol (2011) 1.42
Pro: "Antidote for new anticoagulants"--specific target of inhibition requires a specific target for neutralisation. Thromb Haemost (2012) 1.41
Does pacemaker implantation provide long-term benefits in severe obstructive hypertrophic cardiomyopathy? Rev Esp Cardiol (2009) 1.41
[Efficacy of sirolimus-eluting stents in diabetics with complex coronary lesions]. Rev Esp Cardiol (2006) 1.41
[Plasma concentration of big endothelin-1 and its relation with plasma NT-proBNP and ventricular function in heart failure patients]. Rev Esp Cardiol (2005) 1.38
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost (2009) 1.21
Coronary aneurysms after drug-eluting stents implantation. Eur Heart J (2007) 1.16
Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost (2003) 1.15
Plasma levels of von Willebrand factor are increased in patients with hypertrophic cardiomyopathy. Thromb Res (2010) 1.08
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood (2009) 1.04
Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol (2013) 1.02
Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost (2013) 1.02
Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol (2011) 0.99
Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J (2003) 0.98
Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97
Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status, reparative markers and outcomes. Atherosclerosis (2013) 0.97
Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J (2007) 0.95
Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Am Heart J (2008) 0.95
Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J (2009) 0.94
A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood (2006) 0.94
Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. Haematologica (2005) 0.93
Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail (2010) 0.93
Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med (2011) 0.92
Effect of knee osteoarthritis on the perception of quality of life in Venezuelan patients. Arthritis Rheum (2004) 0.90
Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. Am Heart J (2004) 0.90
Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res (2005) 0.90
Endothelial protein C receptor polymorphisms and risk of myocardial infarction. Haematologica (2008) 0.89
High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac surgery. Eur J Cardiothorac Surg (2013) 0.89
Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) (2012) 0.87
Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thromb Haemost (2014) 0.86
Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab (2009) 0.86
The association of the beta1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica (2007) 0.86
Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke (2003) 0.86
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost (2011) 0.85
Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. Haematologica (2010) 0.85
A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol (2005) 0.85
Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost (2012) 0.84
Are there ethnic differences in the circadian variation in onset of acute myocardial infarction? A comparison of 3 ethnic groups in Birmingham, UK and Alicante, Spain. Int J Cardiol (2005) 0.84
β-Trace protein: from GFR marker to cardiovascular risk predictor. Clin J Am Soc Nephrol (2013) 0.84